A formamide modification (yellow) to a therapeutic agent siRNA (blue) prevents siRNA to bind to non-target mRNA, which allows for treatment with less side effects. Small interfering RNA (siRNA) drugs ...
SEOUL, South Korea--(BUSINESS WIRE)--Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system ...
The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...
siMecA-AGO2 complex inhibits the translation of the mecA gene which encodes the penicillin-binding protein 2a (PBP2a), a protein at the heart of the drug-resistance phenotype in MRSA. By reducing ...
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback